Physician profile
Marek Lukacik
NPI 1225170780
$1,032.07
in general payments reported to CMS, 2019-2025
13 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.59 · 2020: $78.26 · 2021: $140 · 2022: $319 · 2023: $70.54 · 2024: $207 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $319.76 | 2022-2025 | Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $170.39 | 2022-2024 | Dupixent |
| Abbvie INC. | $131.18 | 2019-2021 | |
| Genzyme Corporation | $126.82 | 2024-2025 | |
| Pfizer INC. | $76.22 | 2019-2021 | |
| Travere Therapeutics, INC. | $41.82 | 2019-2020 | |
| Mirum Pharmaceuticals, INC. | $37.78 | 2023-2024 | Livmarli |
| Phadia US INC. | $34.97 | 2022-2025 | Immunocap |
| Nestle Healthcare Nutrition INC. | $23.13 | 2022 | |
| Qol Medical, LLC | $21.47 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.12 | 2024 | Bylvay |
| Pharming Healthcare, INC. | $15.21 | 2023 | Ruconest |
| Albireo Pharma, INC. | $15.20 | 2023 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marek Lukacik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.